Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

NCT07388524 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

336

Enrollment

NIH

Sponsor class

Conditions

Lung Non-Small Cell Carcinoma

Interventions

BIOLOGICAL: Atezolizumab
BIOLOGICAL: Atezolizumab and Recombinant Human Hyaluronidase
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
OTHER: Patient Observation

Sponsor

National Cancer Institute (NCI)